One of many challenges of treating most cancers is the flexibility of most cancers cells to mutate, which ends up in resistance to at present out there therapies. Theseus Prescribed drugs has spent the final two years quietly creating a approach to overcome this drug resistance and selected one of many largest most cancers conferences of the yr to unveil its know-how, with funding of $ 100 million, as she prepares for scientific trials.
Theseus takes a brand new method to tyrosine kinase inhibitors, a kind of drug effectively established within the remedy of most cancers. The mutations result in variants which make these remedies ineffective. Boston-based Theseus takes what he describes as a pan-variant method. The corporate has developed know-how that predicts most cancers mutation, permitting it to focus on identified mutations and keep forward of future variants.
Theseus’ major most cancers goal is gastrointestinal stromal tumor (GIST), a kind of most cancers affecting the gut that may be brought on by mutations within the KIT gene. Sufferers identified with GIST have imatinib as a primary remedy possibility and sunitinib as a second-line remedy. Theseus goals to supply one other tyrosine kinase inhibitor possibility for instances which have superior past second-line remedy.
Theseus has obtained the outcomes of preclinical testing of its flagship program, THE-630. Throughout final week’s annual assembly of the American Affiliation of Most cancers Analysis, the corporate offered knowledge exhibiting that its drug had potent exercise in opposition to all lessons of mutations seen in KIT-mutated GIST. The preclinical research mandatory for a request for a brand new investigational drug are in progress; Theseus plans to start a Part 1 examine within the second half of this yr.
Past GIST, Theseus can be creating a drug designed to selectively block a protein referred to as EGFR with a view to overcome resistance to osimertinib, AstraZeneca’s tyrosine kinase inhibitor, in sufferers with non-toxic lung most cancers. small cells. Theseus has a 3rd drug candidate in improvement for an undisclosed indication.
Theseus was incubated by OrbiMed, which funded the corporate’s 2018 Collection A. Biotechnology is led by a administration crew with expertise at Ariad Prescribed drugs, a developer of most cancers medication primarily based in Cambridge, Massachusetts, which Takeda Pharmaceutical acquired in 2017 for $ 5.2 billion. This biotechnology had commercialized two tyrosine kinase inhibitors, ponatinib and brigatinib. A 3rd, mobocertinib, is in superior scientific improvement.
The final Theseus funding, a Collection B spherical, was led by Foresite Capital. Different buyers in Theseus’ newest spherical embrace Adage Capital Administration, Boxer Capital, Farallon Capital Administration, Longitude Capital, Nextech Ventures, Omega Healthcare Buyers, Pontifax Enterprise Capital, Rock Springs Capital, T. Rowe Value and OrbiMed. Along with the financing, Michael Rome, Managing Director of Foresite, has joined the Board of Administrators of Theseus.
Photograph by Flickr consumer Hey Paul Studios through a Artistic Commons Licence